Association of IFNAR2 rs2236757 and OAS3 rs10735079 Polymorphisms with Susceptibility to COVID-19 Infection and Severity in Palestine

Table 4

Association of IFNAR2 rs2236757 polymorphism with COVID-19 infection among the studied groups.

SNP	Genetic model	Control	Community cases	ICU	Community cases vs. controls: OR (95% CI); value	ICU group vs. control: OR (95% CI); value
rs2236757 (IFNAR2)	Codominant
	GG	33	35	11	ref	ref
	GA	17	35	15	2.14 (0.92–4.94); 0.028	9.55 (1.53–59.47)
	AA	2	0	6	0 (0.0- NA)	6.41 (0.47–87.80); 0.019
	Dominant
	GG	33	35	11	ref	ref
	GA + AA	19	35	21	1.85 (0.82–4.19); 0.134	8.65 (1.60–46.68); 0.005^†
	Recessive
	GG + GA	50	70	26	ref	ref
	AA	2	0	6	0 (0.0- NA); 0.049	2.64 (0.27–26.06); 0.401
	Over dominant
	GG + AA	35	35	17	ref	ref
	GA	17	35	15	2.29 (1.00–5.26); 0.046	6.99 (1.26–38.86); 0.015
	Additive
		52	70	32	1.44 (0.67–3.07); 0.342	3.92 (1.17–13.10); 0.015

^†Best model to explain the association according to the Akaike information criterion. The odds ratios and the values were from logistic regression models adjusted for age, gender, smoking history, history of hypertension, diabetes mellitus, and coronary artery disease. After Bonferroni correction, a value <0.025 was considered significant. ICU, intensive care unit; OR, odds ratio; ref, reference; NA, not applicable. values below the significance threshold are highlighted in bold.